Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
STATE OF NEW YORK
________________________________________________________________________
10466
IN SENATE
May 15, 2026
___________
Introduced by Sen. BOTTCHER -- read twice and ordered printed, and when
printed to be committed to the Committee on Higher Education
AN ACT to amend the education law and the public health law, in relation
to prescription labels for gonadotropin-releasing hormone agonists,
pubertal suppressants, anabolic steroids, alpha reductase inhibitors,
progestins, or drug classes for hormone replacement therapy for treat-
ment of gender dysphoria
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
2 education law, as amended by chapter 108 of the laws of 2025, is amended
3 to read as follows:
4 b-1. Notwithstanding paragraph b of this [section] subdivision, the
5 prescription label for mifepristone [or], misoprostol, gonadotropin-re-
6 leasing hormone agonists, pubertal suppressants, anabolic steroids,
7 alpha reductase inhibitors, progestins, or drug classes for hormone
8 replacement therapy for treatment of gender dysphoria, may include the
9 name or address of the dispensing health care practice instead of the
10 name of the dispenser.
11 § 2. Subdivision 1-a of section 6810 of the education law, as amended
12 by chapter 108 of the laws of 2025, is amended to read as follows:
13 1-a. Notwithstanding subdivision one of this section, at the
14 prescriber's request, the prescription label for mifepristone [or],
15 misoprostol, gonadotropin-releasing hormone agonists, pubertal suppres-
16 sants, anabolic steroids, alpha reductase inhibitors, progestins, or
17 drug classes for hormone replacement therapy for treatment of gender
18 dysphoria, shall include the name or address of the prescribing health
19 care practice instead of the name of the prescriber.
20 § 3. Section 280-d of the public health law, as added by chapter 108
21 of the laws of 2025, is amended to read as follows:
22 § 280-d. Patient notification of prescription label change. A health
23 care prescriber shall inform the patient if such prescriber has included
24 or has requested to include the name or address of the prescribing
25 health care practice instead of the name of such prescriber on the
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD10852-02-6
S. 10466 2
1 prescription label when prescribing mifepristone [or], misoprostol,
2 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic
3 steroids, alpha reductase inhibitors, progestins, or drug classes for
4 hormone replacement therapy for treatment of gender dysphoria.
5 § 4. This act shall take effect immediately.
